Study of Telitacicept in Patients With Refractory IgA Nephropathy

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2026

Conditions

IgA Nephropathy

Interventions

DRUG

Telitacicept

Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for 104 weeks.

Trial Locations (1)

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT05596708 - Study of Telitacicept in Patients With Refractory IgA Nephropathy | Biotech Hunter | Biotech Hunter